Graft Versus Host Disease (GVHD) is a severe medical condition that can occur after a stem cell or bone marrow transplant. In GVHD, the donor's immune cells attack the recipient's healthy tissues ...

Tr1X said that TRX103 could enhance transplant accessibility for patients who lack a matched donor while also minimising GvHD risks. The drug is an off-the-shelf engineered T cell product derived ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

Itolizumab showed significant long-term benefits in acute GVHD, improving complete response duration and failure-free survival. Equillium, Inc. seeks Breakthrough Therapy designation and Accelerated ...

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives. But the biotech brushed off the setback, highlighting other secondary ...

Allogeneic hematopoietic stem cell transplantation (HSCT) is an important and potentially curative treatment of haematological malignancies, but GvHD and infections affect outcomes. We present ...

In addition to her GVHD research, Dr. Flowers studies the effectiveness of using donated lymphocytes, a type of immune cell, to treat recurrent malignancies after transplantation with donated cells.

In his own research, Dr. Carpenter is developing better treatments for graft-vs.-host disease. GVHD is a common complication of bone marrow transplantation that can cause serious illness and even ...